1. Home
  2. VIR

VIR

Vir Biotechnology Inc.

Logo Vir Biotechnology Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Founded: 2016 Country:
United States
United States
Employees: 587 City: SAN FRANCISCO
Market Cap: 1.2B IPO Year: 2019
Target Price: $33.29 AVG Volume (30 days): 1.1M
Analyst Decision: Buy Number of Analysts: 7
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -4.59 EPS Growth: N/A
52 Week Low/High: $7.72 - $27.48 Next Earning Date: 05-02-2024
Revenue: $86,180,000 Revenue Growth: -94.67%
Revenue Growth (this year): -51.52% Revenue Growth (next year): 0.59%

Share on Social Networks: